(Q69499477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

title

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

author name string

M Gore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

R Powles

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

A Lakhani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

S Milan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

J Maitland

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

G Goss

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

A Nandi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

G Forgeson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

J Treleaven

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

publication date

1 January 1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

2 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

2 October 2019

page(s)

373-376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2653659%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00435839

2 October 2019

exact match

0 references

cites work

Prolonged infusion of arabinosyl cytosine in childhood leukemia

1 reference

12 December 2020

Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.

1 reference

12 December 2020

Central nervous system toxicity of high-dose cytosine arabinoside

1 reference

12 December 2020

Advances in the Treatment of Acute Myelogenous Leukemia

1 reference

12 December 2020

Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.

1 reference

12 December 2020

Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside.

1 reference

12 December 2020

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1 reference

12 December 2020

VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults

1 reference

12 December 2020

Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma

1 reference

12 December 2020

Chemotherapy of acute leukemia. Comparison of cytarabine alone and in combination with vincristine, prednisone, and cyclophosphamide

1 reference

12 December 2020

High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma

1 reference

12 December 2020

High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia

1 reference

12 December 2020

Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878)

1 reference

12 December 2020

Cytarabine for acute leukemia in adults. Effect of schedule on therapeutic response

1 reference

12 December 2020

The effects of arabinosylcytosine on cultured human lymphoma cells

1 reference

12 December 2020

Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults

1 reference

12 December 2020

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

1 reference

12 December 2020

A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

High dose cytosine arabinoside in the management of refractory acute leukaemia.

1 reference

12 December 2020

Central nervous system toxicity with high-dose Ara-C.

1 reference

12 December 2020

Central nervous system toxicity of high-dose systemic cytosine arabinoside

1 reference

12 December 2020

Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia

1 reference

12 December 2020

Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.

1 reference

12 December 2020

High-dose cytosine arabinoside therapy for refractory leukemia

1 reference

12 December 2020

High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.

1 reference

12 December 2020

Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia

1 reference

12 December 2020

COMPARATIVE STUDIES OF LEUKEMIC CELLS SENSITIVE AND RESISTANT TO CYTOSINE ARABINOSIDE.

1 reference

12 December 2020

Ocular toxicity from high-dose cytosine arabinoside

1 reference

12 December 2020

High-dose cytosine arabinoside for acute nonlymphocytic leukemia.

1 reference

12 December 2020

Mitozantrone and high-dose cytarabine in adult acute myeloid leukaemia

1 reference

12 December 2020